Mölndal, July 2nd 2025 — We are delighted to announce that distinguished Swedish investors Erik Selin and Jacob Torell have joined Ribocure as new shareholders. Through a direct investment totaling USD 33 million, Erik Selin now holds 32.65% of Ribocure shares, while Jacob Torell holds 1%. We thereby warmly welcome Erik Selin as a new board member of Ribocure.
This investment marks an important milestone in Ribocure’s growth journey in Sweden, underscoring the increasing global interest in RNA-based therapeutics as a transformative therapeutic approach.
With this new investment, Ribocure aims to further develop and to advance its multi-specific siRNA platform and proprietary CNS-delivery technology, enabling significant progress toward groundbreaking therapies for cardiovascular and neurodegenerative disorders.
“We are thrilled to welcome Erik and Jacob to our mission to bring innovative, life-saving therapies to patients,” said Li-Ming Gan, CEO of Ribocure. “It is very exciting to see leading oligonucleotide researchers, experienced drug developers, and renowned entrepreneurs joining forces to achieve our vision of improving global health. This investment not only validates our scientific and technological platforms but also greatly enhances our capacity to expand our global impact at an accelerated pace.”
Ribocure Pharmaceuticals, located at GoCo Health Innovation City, is a pioneering Swedish biotech company dedicated to developing advanced siRNA-based therapies to address some of today’s most urgent medical challenges.
Media Contact: Malin Westberg Business Planning Lead malin.westberg@ribocure.com www.ribocure.com
